leisure time -WSS

leisure time

author：leisure time 2025-08-10 11:42:21 - browse：821

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medicare Advantage enrollment hits roughly 33.4 million

entertainment

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Researchers tackle phage therapy hurdles for wider adoption

Obamacare plans could cover weight loss drugs

Reporting on presidential health from Reagan to Trump and Biden

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

entertainment

leisure time

hotspot

How to save PrEP access — and even expand it

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Continuity nursing helped my family in our darkest PICU moments

In 'major milestone,' FDA approves first cell therapy for solid tumors

Malaria cases in Florida and Texas: Here’s what you need to know

In 'major milestone,' FDA approves first cell therapy for solid tumors

What does generative AI mean for health care? We asked experts

Measles policy set amid Florida outbreak alarms vaccine proponents

How to save PrEP access — and even expand it

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

In 'major milestone,' FDA approves first cell therapy for solid tumors

Flagship Pioneering startup Sonata Therapeutics lays off 21

A new drug could help frostbite victims avoid its ravages

Medicare Advantage enrollment hits roughly 33.4 million

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

entertainment

hotspot

entertainment

entertainment